Torrent Pharma share price in focus: Torrent Pharma, a leading pharma company in India, a constituent of the BSE 200, announced its financial results for the fourth quarter of FY26 on May 22. The company reported its Q4 FY26 results, with a consolidated net profit of Rs 389 crore, down 22 per cent YoY from Rs 498 crore in Q4 FY25. Despite the drop in net profit due to higher integration expenses, the company posted its highest-ever quarterly revenue at Rs 4,197 crore, a 42 per cent YoY increase.

The Board has recommended a final dividend of Rs 9 per equity share of face value of Rs 5. Following its Q4 results, the brokerages have shared their mixed stance on this pharma stock. Check out their ratings if you are planning to buy, sell, hold or add this stock.

Read more: FMCG Stock to BUY: Brokerages bullish on Emami despite weak Q4 results - Here's why

Torrent Pharma share price in focus: Brokerages' ratings - Check latest target price

Nuvama on Torrent Pharma

The brokerage maintains a buy rating with a target price of Rs 5170 (earlier 4700). Here is why:

• Semaglutide shines; JB strengthens the story
• Base business remains robust; acquisition costs affect PAT
• JB merger in final stages; retain 'BUY'
• Building in revenue/EBITDA CAGR of 14%/28% over FY26-28E

DAM Capital Research on Torrent Pharma

DAM Capital Research maintains a buy call target price of Rs 4,941 based on consolidated financials (23x EV/EBITDA (FY28E). Reasons being:

• Torrent remains one of the most consistent performers amongst peers on the back
• of steady India growth and strong cost management.
• Going ahead, on the core business, the brokerage expects exports to pick up to provide a further boost to profitability, with the pick-up in the US supporting the momentum in Brazil and RoW (BGx markets).
• Potential launch of gSema in India in FY27E and Brazil can provide upsides, given Torrent's right to win in both markets.
• Along with steady scale-up in core, the brokerage sees meaningful opportunities for value
• creation in JB Chemical - mgt guidance on cost synergies adds comfort.
• Expect clarity on revenue synergies and other integration gains in the coming quarters.

Nirmal Bang on Torrent Pharma

The brokerage maintains HOLD on Torrent Pharma with a target price of Rs 4,898, valuing the company at 24x FY28E EV/EBITDA, implying 10% premium to its 5-year average multiple.

Torrent Pharma's (TRP) 4QFY26 consolidated results came in ahead of NBIE estimates, largely aided by the consolidation of JB Pharma from 21-Jan-26; however, the standalone/base business performance remained broadly in line with estimates.

Excluding JB Pharma, Torrent delivered 16% YoY revenue growth with EBITDA margin sustained at 32.7%, supported by continued strong traction across key branded markets.

India business outperformed the IPM led by chronic therapies, Curatio scale-up and early success in semaglutide launches, while Brazil maintained healthy momentum driven by new launches and pricing actions. The US business continued to recover, aided by recent launches and improved offtake from existing products.

During the quarter, Torrent consolidated JB Pharma following the acquisition of a controlling stake, marking a key strategic milestone for the company.

The management remains optimistic on sustaining strong growth momentum across key markets, supported by semaglutide scale-up, differentiated India launches, continued Brazil traction and synergy benefits from the JB Pharma integration.

While the JB Pharma acquisition strengthens Torrent's India franchise and medium-term growth visibility, current valuations largely factor in the near-term earnings and synergy benefits.